• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>EJNMMI Research >Comparison of Tc-99m maraciclatide and Tc-99m sestamibi molecular breast imaging in patients with suspected breast cancer
【24h】

Comparison of Tc-99m maraciclatide and Tc-99m sestamibi molecular breast imaging in patients with suspected breast cancer

机译：Tc-99m maraciclatide与Tc-99m sestamibi分子乳腺成像在可疑乳腺癌患者中的比较

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Molecular breast imaging (MBI) performed with 99mTc sestamibi has been shown to be a valuable technique for the detection of breast cancer. Alternative radiotracers such as 99mTc maraciclatide may offer improved uptake in breast lesions. The purpose of this study was to compare relative performance of 99mTc sestamibi and 99mTc maraciclatide in patients with suspected breast cancer, using a high-resolution dedicated gamma camera for MBI. Women with breast lesions suspicious for malignancy were recruited to undergo two MBI examinations—one with 99mTc sestamibi and one with 99mTc maraciclatide. A radiologist interpreted MBI studies in a randomized, blinded fashion to assign an assessment score (1–5) and measured lesion size. Lesion-to-background (L/B) ratio was measured with region-of-interest analysis. Among 39 analyzable patients, 21 malignant tumors were identified in 21 patients. Eighteen of 21 tumors (86%) were seen on 99mTc sestamibi MBI and 19 of 21 (90%) were seen on 99mTc maraciclatide MBI (p?=?1). Tumor extent measured with both radiopharmaceuticals correlated strongly with pathologic size (99mTc sestamibi, r?=?0.84; 99mTc maraciclatide, r?=?0.81). The L/B ratio in detected breast cancers was similar for the two radiopharmaceuticals: 1.55?±?0.36 (mean?±?S.D.) for 99mTc sestamibi and 1.62?±?0.37 (mean?±?S.D.) for 99mTc maraciclatide (p?=?0.53). No correlation was found between the L/B ratio and molecular subtype for 99mTc sestamibi (r s ?=?0.12, p?=?0.63) or 99mTc maraciclatide (r s ?=??0.12, p?=?0.64). Of 20 benign lesions, 10 (50%) were seen on 99mTc sestamibi and 9 of 20 (45%) were seen on 99mTc maraciclatide images (p?=?0.1). The average L/B ratio for benign lesions was 1.34?±0.40 (mean?±S.D.) for 99mTc sestamibi and 1.41?±0.52 (mean?±S.D.) for 99mTc maraciclatide (p?=?0.75). Overall diagnostic performance was similar for both radiopharmaceuticals. AUC from ROC analysis was 0.83 for 99mTc sestamibi and 0.87 for 99mTc maraciclatide (p?=?0.64). 99mTc maraciclatide offered comparable lesion uptake to 99mTc sestamibi, in both malignant and benign lesions. There was good correlation between lesion extent and uptake measured from both radiopharmaceuticals. 99mTc maraciclatide offered a marginal (but not significant) improvement in sensitivity over 99mTc sestamibi. Our findings did not support an association between the uptake of either radiopharmaceutical and tumor molecular subtype. ClinicalTrials.gov, NCT00888589
机译：99mTc sestamibi进行的分子乳腺成像（MBI）已被证明是检测乳腺癌的有价值的技术。诸如99mTc maraciclatide之类的其他放射性示踪剂可能会改善乳腺病变的摄取。这项研究的目的是使用高分辨率专用伽玛相机对MBI进行比较，比较99mTc sestamibi和99mTc maraciclatide在可疑乳腺癌患者中的相对表现。招募了患有可疑恶性乳腺病变的女性，接受了两次MBI检查-一位接受99mTc的司他他比，另一位接受99mTc的马来酸。放射科医生以随机，盲法方式对MBI研究进行解释，以分配评估评分（1-5）和测量的病灶大小。病变与背景（L / B）的比率是通过感兴趣区域分析来测量的。在39例可分析的患者中，21例患者中鉴定出21例恶性肿瘤。在99mTc的sestamibi MBI上观察到21个肿瘤中的18个（86％），在99mTc的maraciclatide MBI上观察到21个肿瘤中的19个（90％）（p？=？1）。用两种放射性药物测得的肿瘤程度与病理学大小密切相关（99mTc sestamibi，r = 0.84; 99 mT maraciclatide，r = 0.81）。两种放射性药物在检测到的乳腺癌中的L / B比值相似：99mTc的西司他比为1.55±±0.36（平均值±±标准差），而99mTc的马拉西肽（p = 1.52±0.33）（平均值±±标准差）。 =？0.53）。没有发现L / B比与99mTc sestamibi（r s ＝ 0.12，p ＝ 0.63）或99mTc maraciclatide（r s ＝ 0.12，p ＝ 0.64）的分子亚型之间没有相关性。在20mT良性病变中，在99mTc sestamibi上观察到10个（50％），在99mTc maraciclatide图像上观察到20个（9％）（45％）（p≤0.1）。良性病变的平均L / B比对于99mTc的sestamibi为1.34？±0.40（平均值？±S.D。）和对于99mTc的马拉西肽为1.41？±0.52（平均值？±S.D。）（p？=？0.75）。两种放射性药物的总体诊断性能相似。 ROC分析得出的99mTc sestamibi的AUC是0.83，而99mTc马拉西肽的AUC是0.87（p？=？0.64）。在恶性和良性病变中，99mTc maraciclatide的病灶摄取与99mTc sestamibi相当。两种放射性药物测定的病变程度和摄取之间有良好的相关性。与99mTc的西他米比相比，99mTc的马拉西替利的敏感性稍有提高（但不显着）。我们的发现不支持放射性药物的摄取与肿瘤分子亚型之间的关联。 ClinicalTrials.gov，NCT00888589

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号